Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy

被引:70
作者
Lévy, M
Copie-Bergman, C
Gameiro, C
Chaumette, MT
Delfau-Larue, MH
Haioun, C
Charachon, A
Hemery, F
Gaulard, P
Leroy, K
Delchier, JC
机构
[1] Hop Henri Mondor, Dept Pathol, Serv Hepatol & Gastroenterol, F-94000 Creteil, France
[2] Hop Henri Mondor, INSERM, U617, F-94000 Creteil, France
[3] Hop Henri Mondor, Serv Immunol Biol, F-94000 Creteil, France
[4] Hop Henri Mondor, Serv Hematol, F-94000 Creteil, France
[5] Hop Henri Mondor, Serv Biostat & Informat, F-94000 Creteil, France
关键词
D O I
10.1200/JCO.2005.05.660
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To determine the impact of translocation t(11;18) on response to oral alkylating agents in gastric mucosa-associated lymphoid tissue lymphoma (GML). Patients and Methods Fifty-three patients with a GML were studied. Helicobacter pylori-positive patients (n = 34) received anti-H pylori treatment and H pylori-negative patients (n = 19) or patients who failed to respond to anti-H pylori treatment received oral alkylating agents. t(11;18) was detected by reverse transcription polymerase chain reaction from frozen gastric biopsies. Results t(11;18) was detected in 32% of patients. It was more prevalent in H pylori-negative as compared with H pylori-positive patients (12 of 19 v five of 34 patients; P =.0005). Among 31 H pylori-eradicated patients, t(11;18) was detected in three patients, all of whom experienced treatment failure, and it was absent in 28 patients: 21 patients (75%) were in remission and seven patients (25%) experienced treatment failure (P =.03). Among 21 patients who received an alkylating agent, t(11;18) was detected in 12 patients: five patients (42%) were in remission and seven patients (58%) experienced treatment failure. t(11;18) was absent in nine patients: eight patients (89%) were in remission and one patient (11 %) experienced treatment failure by the end of treatment. Four patients in remission relapsed during follow-up (median, 7 years): they all had t(11;18). Durable remission was obtained in eight (89%) of the nine patients without t(11;18) versus one of the 12 patients (8%) with t(11;18) (P=.0003). Conclusion Presence of t(11;18) in GML is predictive of resistance to oral alkylating agents, with less than 10% of durable remission at long-term follow-up.
引用
收藏
页码:5061 / 5066
页数:6
相关论文
共 34 条
  • [1] Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection
    Alpen, B
    Neubauer, A
    Dierlamm, J
    Marynen, P
    Thiede, C
    Bayerdörffer, E
    Stolte, M
    [J]. BLOOD, 2000, 95 (12) : 4014 - 4015
  • [2] The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation
    Baens, M
    Steyls, A
    Geboes, K
    Marynen, P
    De Wolf-Peeters, C
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04) : 1433 - 1439
  • [3] REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION
    BAYERDORFFER, E
    NEUBAUER, A
    RUDOLPH, B
    THIEDE, C
    LEHN, N
    EIDT, S
    STOLTE, M
    [J]. LANCET, 1995, 345 (8965): : 1591 - 1594
  • [4] LOW-GRADE B-CELL MUCOSA ASSOCIATED LYMPHOID-TISSUE LYMPHOMA OF THE STOMACH - CLINICAL AND ENDOSCOPIC FEATURES, TREATMENT, AND OUTCOME
    BLAZQUEZ, M
    HAIOUN, C
    CHAUMETTE, MT
    GAULARD, P
    REYES, F
    SOULE, JC
    DELCHIER, JC
    [J]. GUT, 1992, 33 (12) : 1621 - 1625
  • [5] Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
    Conconi, A
    Martinelli, G
    Thiéblemont, C
    Ferreri, AJM
    Devizzi, L
    Peccatori, F
    Ponzoni, M
    Pedrinis, E
    Dell'Oro, S
    Pruneri, G
    Filipazzi, V
    Dietrich, PY
    Gianni, AM
    Coiffier, B
    Cavalli, F
    Zucca, E
    [J]. BLOOD, 2003, 102 (08) : 2741 - 2745
  • [6] Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma
    Copie-Bergman, C
    Gaulard, P
    Lavergne-Slove, A
    Brousse, N
    Fléjou, JF
    Dordonne, K
    de Mascarel, A
    Wotherspoon, AC
    [J]. GUT, 2003, 52 (11) : 1656 - 1656
  • [7] The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas
    Dierlamm, J
    Baens, M
    Wlodarska, I
    Stefanova-Ouzounova, M
    Hernandez, JM
    Hossfeld, DK
    De Wolf-Peeters, C
    Hagemeijer, A
    Van den Berghe, H
    Marynen, P
    [J]. BLOOD, 1999, 93 (11) : 3601 - 3609
  • [8] EFFICACY OF SINGLE-AGENT CHEMOTHERAPY IN LOW-GRADE B-CELL MUCOSA-ASSOCIATED LYMPHOID-TISSUE LYMPHOMA WITH PROMINENT GASTRIC EXPRESSION
    HAMMEL, P
    HAIOUN, C
    CHAUMETTE, MT
    GAULARD, P
    DIVINE, M
    REYES, F
    DELCHIER, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) : 2524 - 2529
  • [9] Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion
    Inagaki, H
    Nakamura, T
    Li, CM
    Sugiyama, T
    Asaka, M
    Kodaira, J
    Iwano, M
    Chiba, T
    Okazaki, K
    Kato, A
    Ueda, R
    Eimoto, T
    Okamoto, S
    Sasaki, N
    Uemura, N
    Akamatsu, T
    Miyabayashi, H
    Kawamura, Y
    Goto, H
    Niwa, Y
    Yokoi, T
    Seto, M
    Nakamura, S
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (12) : 1560 - 1567
  • [10] ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO